GVHD vs Relapse

Blood stem cell transplants offer a lifeline for many blood cancer patients.

Success depends on a delicate balance: the donor’s immune cells must attack the cancer (the GvL effect) without targeting the patient's healthy tissue (GVHD).

Immunomatics is developing predictive models to assess the dual risks of GVHD and relapse and help clinicians improve donor selection and patient outcomes.

Check the link below to learn more.
wefunder.com/immunomatics